유럽의 급성기 신드로믹 검사 시장 - 분석 및 예측(2023-2033년)

“The Europe Acute Care Syndromic Testing Market Expected to Reach $2.32 Billion by 2033.”

Introduction to Europe Acute Care Syndromic Testing Market

The Europe acute care syndromic testing market was valued at $0.90 billion in 2022 and is expected to reach $2.32 billion by 2033, growing at a CAGR of 8.95% between 2023 and 2033. Molecular diagnostics techniques such as syndromic panels are capable of simultaneously detecting several pathogens. These pathogens typically exhibit comparable or overlapping clinical symptomatology, making patient management easier and specific symptom diagnosis more straightforward.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$0.98 Billion
2033 Forecast	$2.32 Billion
CAGR	8.95%

Market Introduction

The increasing demand for early infectious illness identification has led to a notable surge in the acute care syndromic testing industry in Europe. The incidence of pandemics and the prevalence of infectious diseases have been major contributors to this rise. Furthermore, the expansion of the industry has been aided by the rise in global temperatures and the discovery of new infectious diseases in different places.

Promising healthcare solutions are available in the European acute care syndromic testing sector, and more developments may be possible. The acute care syndromic testing market is growing as a result of the advancement of instruments for early detection, treatment planning, diagnosis, and monitoring of infectious diseases. The Europe market is witnessing increasing investments in healthcare infrastructure and the adoption of advanced diagnostic technologies, further boosting the growth of the acute care syndromic panel testing market. Additionally, favorable regulations and initiatives promoting the integration of syndromic panel testing in routine clinical.

Market Segmentation

Segmentation 1: by End User

• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutions
• Other End Users

Segmentation 2: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Europe acute care syndromic testing market has been extensively segmented on the basis of various categories, such as end user and Country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the Europe acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

Table of Contents

1 Markets

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion Criteria
• 1.3 Market Scope
  • 1.3.1 Key Questions Answered in the Report
• 1.4 Research Methodology
  • 1.4.1 Acute Care Syndromic Testing Market: Research Methodology
  • 1.4.2 Data Sources
    • 1.4.2.1 Primary Data Sources
    • 1.4.2.2 Secondary Data Sources
  • 1.4.3 Market Estimation Model
  • 1.4.4 Criteria for Company Profiling

2 Market Overview

• 2.1 Overview
• 2.2 Acute Care Syndromic Testing Workflow Analysis
• 2.3 Market Footprint and Growth Potential
• 2.4 Future Potential

3 Industry Insight

• 3.1 Stakeholder's Perspective (N=20)
  • 3.1.1 Physician's Perception
  • 3.1.2 Payor's Perception
  • 3.1.3 Investor's Perception
• 3.2 Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
  • 3.2.1 Regulatory Framework in North America
    • 3.2.1.1 The U.S.
    • 3.2.1.2 Canada
  • 3.2.2 Regulatory Framework in Europe
  • 3.2.3 Regulatory Framework in Asia-Pacific
    • 3.2.3.1 Japan
    • 3.2.3.2 China
    • 3.2.3.3 India
    • 3.2.3.4 South Korea
    • 3.2.3.5 Australia
  • 3.2.4 Regulatory Framework in Latin America
    • 3.2.4.1 Brazil
    • 3.2.4.2 Mexico
  • 3.2.5 Regulatory Framework in Rest-of-the-World
    • 3.2.5.1 U.A.E.
    • 3.2.5.2 K.S.A.
• 3.3 Product Benchmarking

4 Market Dynamics

• 4.1 Overview
• 4.2 Impact Analysis
• 4.3 Market Drivers
  • 4.3.1 Faster Results Acquired with Syndromic Tests
  • 4.3.2 Increasing Incidence of Infectious Diseases
  • 4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
  • 4.3.4 Reduced Severe Adverse Effects from Pathogens
• 4.4 Market Challenges
  • 4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
  • 4.4.2 Lack of High-Complexity Testing Centres
• 4.5 Market Opportunities
  • 4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
  • 4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5 Europe

• 5.1 Overview
• 5.2 Europe
  • 5.2.1 Europe Acute Care Syndromic Testing Market, By End User
  • 5.2.2 Europe Acute Care Syndromic Testing Market, By Country
    • 5.2.2.1 Germany
    • 5.2.2.2 France
    • 5.2.2.3 U.K.
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest-of-Europe

6 Company Profiles

• 6.1 Overview
• 6.2 Acute Care Syndromic Testing Ecosystem Active Players
• 6.3 Biocartis NV
  • 6.3.1 Company Overview
  • 6.3.2 Role of Biocartis NV in the Acute Care Syndromic Testing Market
  • 6.3.3 Financials
  • 6.3.4 Recent Developments
    • 6.3.4.1 Business Strategies
  • 6.3.5 Analyst Perspective
• 6.4 bioMerieux SA (BioFire Diagnostics)
  • 6.4.1 Company Overview
  • 6.4.2 Role of bioMerieux SA (BioFire Diagnostics) in the Acute Care Syndromic Testing Market
  • 6.4.3 Financials
  • 6.4.4 Recent Developments
    • 6.4.4.1 Business Strategies
  • 6.4.5 Analyst Perspective
• 6.5 DiaSorin S.p.A (Luminex Corporation)
  • 6.5.1 Company Overview
  • 6.5.2 Role of DiaSorin S.p.A (Luminex Corporation) in the Acute Care Syndromic Testing Market
  • 6.5.3 Financials
  • 6.5.4 Recent Developments
    • 6.5.4.1 Corporate Strategies
    • 6.5.4.2 Business Strategies
  • 6.5.5 Analyst Perspective
• 6.6 Eurofins Scientific (Eurofins Viracor)
  • 6.6.1 Company Overview
  • 6.6.2 Role of Eurofins Scientific (Eurofins Viracor) in the Acute Care Syndromic Testing Market
  • 6.6.3 Financials
  • 6.6.4 Recent Developments
    • 6.6.4.1 Business Strategies
  • 6.6.5 Analyst Perspective
• 6.7 QIAGEN N.V.
  • 6.7.1 Company Overview
  • 6.7.2 Role of QIAGEN N.V. in the Acute Care Syndromic Testing Market
  • 6.7.3 Financials
  • 6.7.4 Recent Developments
    • 6.7.4.1 Business Strategies
  • 6.7.5 Analyst Perspective
• 6.8 QuantuMDx Group Ltd.
  • 6.8.1 Company Overview
  • 6.8.2 Role of QuantuMDx Group Ltd. in the Acute Care Syndromic Testing Market
  • 6.8.3 Recent Developments
    • 6.8.3.1 Corporate Strategies
    • 6.8.3.2 Business Strategies
  • 6.8.4 Analyst Perspective
• 6.9 Siemens Healthineers AG
  • 6.9.1 Company Overview
  • 6.9.2 Role of Siemens Healthineers AG in the Acute Care Syndromic Testing Market
  • 6.9.3 Financials
  • 6.9.4 Analyst Perspective